ZUG, Switzerland--(BUSINESS WIRE)--Galderma announced today positive topline results from the phase III READY-3 clinical trial investigating the use of RelabotulinumtoxinA for the treatment of ...

Please provide your email address to receive an email when new articles are posted on . 92%, 62% and 60% of subjects were satisfied with their outcomes at months 1, 6 and 12 post-treatment, ...

Please provide your email address to receive an email when new articles are posted on . Both phase 3b studies met their primary endpoints of improved frown lines and crow’s feet. A majority of ...

(Reuters) - An injection to treat forehead wrinkles is set to rival Allergan's Botox after U.S. regulators approved Evolus Inc's cheaper treatment on Friday, sending its shares up about 5 percent ...

(Reuters) - Medical aesthetics company Revance Therapeutics Inc said on Tuesday that its long-acting injectable drug was successful in reducing moderate-to-severe frown lines in a late-stage study.

Revance Therapeutics' share price has been characterised by volatility ever since its IPO - but today shares trade close to an all-time low. The company's focus is on maximising the potential of ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Who doesn’t love sitting down with Dr. Margo ...

91% of Americans say they're more ingredient-conscious than ever, yet more than half mistakenly believe all frown line treatments are the same NASHVILLE, Tenn., Sept. 23, 2025 /PRNewswire/ -- From ...